A clinical trial update dated September 29, 2026 reports on a study titled "Effect of Weekly GLP1 Agonist Treatment in 'Double Diabetes.'" The trial, registered as NCT05305794, is listed as Phase 3. Its current status is recruiting, according to the update. Dulaglutide, an approved GLP-1 receptor agonist, is the weekly treatment referenced in the trial title. The update does not report results or outcome data at this stage. No efficacy or safety conclusions have been disclosed as part of this status update. The trial record indicates the study remains open to participant enrollment as of the listed date. No additional details regarding trial design, patient population specifics, or endpoints were included in this update beyond the trial title and status. Readers should note that a recruiting status reflects an ongoing research phase, not a completed study with findings. Further updates on this trial may provide additional information as the study progresses. For more background on dulaglutide, including its approved regulatory status, readers can consult the compound overview.
Dulaglutide Phase 3 "Double Diabetes" Trial Status: Recruiting
See the full dulaglutide overview
Source: https://clinicaltrials.gov/study/NCT05305794